271
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
Condition(s):Multiple MyelomaLast Updated:January 30, 2023Recruiting
Refractory Multiple Myeloma: 1467 Clinical Trials, Page 28 of 147
Hide Studies Not Open or Pending
272
TriPRIL CAR T Cells in Multiple Myeloma
Condition(s):Multiple Myeloma; Multiple Myeloma in Relapse; Refractory Multiple MyelomaLast Updated:March 15, 2023Recruiting
273
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 4, 2023Active, not recruiting
274
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:July 20, 2022Terminated
275
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:August 5, 2022Active, not recruiting
276
Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:May 30, 2012Completed
277
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 6, 2023Recruiting
278
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 15, 2023Recruiting
279
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 29, 2022Not yet recruiting
280
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 6, 2023Active, not recruiting